Clinical Trials Browser

OTHER × Cisplatin × Clear all

NCT02135042 2026-03-18

Individualized Treatment in Treating Patients With Stage II-IVB Nasopharyngeal Cancer Based on EBV DNA

Phase 2/3 Active not recruiting

Nasopharyngeal Carcinoma, Epstein-Barr Virus Infections

NCT03418038 2026-03-18

Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia

Phase 2 Recruiting

LymphoidOther hematologic neoplasm

Hodgkin Disease, Lymphoma, Leukemia, Myelomonocytic, Chronic, Lymphoma, Large B-Cell, Diffuse

NCT05941741 2026-03-18

IC Plus Low-dose Radiation Plus Cadonilimab in LANPC

Phase 3 Recruiting

Nasopharyngeal Carcinoma

NCT01612351 2026-03-17

Multimodality Risk Adapted Tx Including Induction Chemo for SCCHN Amenable to Transoral Surgery

Phase 2 Completed

40 enrolled 20 charts

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell, Head and Neck Neoplasms

NCT02114229 2026-03-17

SJATRT

Phase 2 Active not recruiting

Rhabdoid Tumor

NCT07477457 2026-03-17

A Study of Gefitinib, Trametinib, Disulfiram, and Sunitinib in Addition to Standard Chemotherapy in People With Osteosarcoma

Phase 2 Recruiting

Neoplasm Metastasis, Osteosarcoma

NCT06538038 2026-03-16

Prospective Non-Interventional Study Comparing Osimertinib +/- Chemotherapy for EGFR-Mutated NSCLC Patients

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT07459296 2026-03-16

Becotatug Vedotin Plus Sintilimab in Locoregionally Advanced NPC

Phase 3 Recruiting

Nasopharyngeal Carcinoma

NCT05285358 2026-03-13

Pressurized Intraperitoneal Aerosolized Nab-Paclitaxel in Combination With Gemcitabine and Cisplatin for the Treatment of Biliary Tract Cancer Patients With Peritoneal Metastases

Phase 1 Recruiting

Gastrointestinal

Gallbladder Neoplasms, Cholangiocarcinoma

NCT05521997 2026-03-13

Glutaminase Inhibition and Chemoradiation in Advanced Cervical Cancer

Phase 2 Not yet recruiting

Uterine Cervical Neoplasms

NCT07332351 2026-03-13

TRIFECTA

Phase 2 Not yet recruiting

Urinary Bladder Neoplasms

NCT07078604 2026-03-12

A Cancer Vaccine (STEMVAC) in Combination With Chemotherapy for the Treatment of PD-L1 Negative Metastatic Triple-Negative Breast Cancer

Phase 2 Recruiting

Triple Negative Breast Neoplasms

NCT05819892 2026-03-11

Phase I Trial Testing the Safety and Tolerability of Chemoradiation Followed by Chemotherapy + Dostarlimab for Stage IIIC, Node Positive, Endometrial Cancer

Phase 1 Recruiting

Endometrial Neoplasms

NCT07463313 2026-03-11

6 vs 3 Cycles of Neoadjuvant Chemotherapy for Potentially Resectable Locally Advanced Thymic Epithelial Tumors

Phase 2/3 Not yet recruiting

Thymic epithelial tumor, Mediastinal Neoplasms, Thymoma

NCT02402920 2026-03-10

Pembrolizumab and Concurrent Chemoradiotherapy or Radiation Therapy in Treating Patients With Small Cell Lung Cancer

Phase 1 Completed

83 enrolled 13 charts

Neuroendocrine Tumors

NCT05689671 2026-03-10

ANTELOPE

Phase 4 Active not recruiting

Non-Small Cell Lung Cancer Metastatic

NCT04030455 2026-03-09

Cisplatin, Docetaxel, and Pembrolizumab in Treating Patients With Stage II-III Laryngeal Cancer

Phase 2 Active not recruiting

28 enrolled 13 charts

Squamous Cell Carcinoma of Head and Neck, Laryngeal Neoplasms

NCT05491512 2026-03-09

A Study of Reduced Radiation Therapy and Standard-of-Care Chemotherapy in People With HPV-Positive Throat Cancer

Phase 2 Recruiting

Oropharyngeal Neoplasms

NCT07209189 2026-03-09

(NeoScorch HN)

Phase 2 Recruiting

Carcinoma, Squamous Cell, Head and Neck Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms, Papillomavirus Infections

NCT03322267 2026-03-06

Adjuvant Pembrolizumab for Patients With Locally Advanced Esophageal Squamous Cell Carcinoma at High Risk of Recurrence

Phase 2 Completed

26 enrolled 6 charts

Gastrointestinal

Esophageal Squamous Cell Carcinoma

NCT05502250 2026-03-06

HOVON164HL

Phase 2 Active not recruiting

Hodgkin Disease

NCT06239727 2026-03-06

Reduced-dose Radiotherapy for Stage III Nasopharyngeal Carcinoma Based on the Treatment Response

Phase 3 Recruiting

Nasopharyngeal Carcinoma

NCT00707473 2026-03-05

Docetaxel, Cisplatin and Fluorouracil in Treating Patients With Previously Untreated Stage II-IV Nasal Cavity and Paranasal Sinus Cancer

Phase 2 Active not recruiting

Sinonasal undifferentiated carcinoma, Paranasal Sinus Neoplasms

NCT01970722 2026-03-05

Surgery and Chemotherapy With or Without Chemotherapy After Surgery in Treating Patients With Ovarian, Fallopian Tube, Uterine, or Peritoneal Cancer

Phase 1 Active not recruiting

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT07452601 2026-03-05

Time-of-Day of Immunotherapy Infusion in Neoadjuvant Immunochemotherapy for Thoracic ESCC

Phase 2 Not yet recruiting

Gastrointestinal

Esophageal Squamous Cell Carcinoma

NCT03609216 2026-03-04

Gemcitabine and Cisplatin Without Cystectomy for Patients With Muscle Invasive Bladder Urothelial Cancer and Select Genetic Alterations

Phase 2 Recruiting

Infiltrating Bladder Urothelial Carcinoma

NCT06632327 2026-03-04

Comparing Impact of Treatment Before or After Surgery in Patients With Stage II-IIIB Resectable Non-small Cell Lung Cancer

Phase 3 Recruiting

Lung Neoplasms

NCT07327216 2026-03-04

Sapylin Versus Dexamethasone Inhalation for CCRT-Induced Oral Mucositis in Nasopharyngeal Carcinoma

Phase 3 Recruiting

Nasopharyngeal Carcinoma

NCT05050162 2026-03-03

Comparing Cisplatin Every Three Weeks to Cisplatin Weekly When Combined With Radiation for Patients With Advanced Head and Neck Cancer

Phase 2/3 Suspended

Carcinoma, Oropharyngeal Neoplasms

NCT06208826 2026-03-03

A Single-center Phase II Study to Investigate the Immune Maintenance Therapy Pattern in Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma Who Have Achieved MPR After Neoadjuvant Immunotherapy Combined With Chemotherapy

Phase 2 Recruiting

Head and Neck Neoplasms

NCT02031250 2026-03-02

Randomized Phase II Study of DCE-MRI-based Dose Escalation for Poor-prognosis and Neck Cancer

Phase 2 Completed

106 enrolled 12 charts

Squamous Cell Carcinoma of Head and Neck

NCT05681039 2026-03-02

Phase 2 Trial of Neoadjuvant and Adjuvant Tiragolumab Plus Atezolizumab in Patients With Newly Diagnosed PD-L1 CPS Positive Resectable Stage 3-4 Oral Cavity Squamous Cell Carcinoma (OCSCC).

Phase 2 Recruiting

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell

NCT07026474 2026-03-02

RePaIr-HN

Phase 3 Recruiting

Squamous Cell Carcinoma of Head and Neck

NCT07039162 2026-02-27

Study of Tislelizumab Combined With Chemoradiotherapy and Surgery for Unresectable Esophageal Squamous Cell Carcinoma

Phase 2 Recruiting

Gastrointestinal

Esophageal Squamous Cell Carcinoma

NCT03774732 2026-02-25

NIRVANA-LUNG

Phase 3 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT05753306 2026-02-25

Robotic Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy for Treatment of Gastric Cancer With Limited Peritoneal Metastasis, ROBO-CHIP Study

Phase 2 Recruiting

GastrointestinalOther neoplasm

Gastric Adenocarcinoma

NCT04620187 2026-02-24

Post-op T-DM1 in HER-2+ Salivary Gland Carcinomas

Phase 2 Recruiting

Salivary Gland Neoplasms

NCT03174275 2026-02-23

Carboplatin, Nab-Paclitaxel, Durvalumab Before Surgery and Adjuvant Therapy in Head and Neck Squamous Cell Carcinoma

Phase 2 Active not recruiting

39 enrolled 8 charts

GastrointestinalHead & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell, Esophageal Neoplasms, Laryngeal Neoplasms, Lip Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms

NCT00003042 2026-02-20

Chemotherapy and Stem Cell Transplantation in Treating Patients With Stage IIIB Breast Cancer

Phase 2 Completed

41 enrolled 9 charts

Breast Neoplasms, Inflammatory Breast Neoplasms

NCT03366766 2026-02-20

Nivolumab Plus Cisplatin/Pemetrexed or Cisplatin/Gemcitabine as Induction in Resectable Non-Small Cell Lung Cancer

Phase 2 Terminated

14 enrolled 16 charts

Carcinoma, Non-Small-Cell Lung

NCT05403723 2026-02-19

Adaptive SBRT Plus Chemoimmunotherapy for ES-SCLC

Phase 1 Suspended

Lung Neoplasms, Small Cell Lung Carcinoma

NCT05137262 2026-02-18

A Phase II Multicenter Study of Chemotherapy Versus Chemotherapy Plus Durvalumab (MEDI 4736) in Patients With Lymph Node Positive Urothelial Carcinoma of the Bladder

Phase 2 Active not recruiting

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT05268614 2026-02-18

Risk Adapted De-Intensification of Radio-Chemotherapy for Oropharyngeal Squamous Cell Carcinoma

Phase 2 Recruiting

Squamous Cell Carcinoma of Head and Neck

NCT07418866 2026-02-18

FANLUNG-2：The Value of High-Low Mixed-Dose Radiotherapy Combined With Chemo-Immunotherapy Induction in Locally Advanced Non-Small Cell Lung Cancer

Phase 2 Not yet recruiting

Carcinoma, Non-Small-Cell Lung

NCT07418931 2026-02-18

CECYDE

Phase 2 Not yet recruiting

Advanced Squamous Non-Small Cell Lung Cancer

NCT05075980 2026-02-13

Intensity Modulated Proton or X-Ray Therapy After Surgery for Treatment of Head and Neck Cancer, the HEADLIGHT Study

Phase 2 Recruiting

Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Lymphatic Metastasis, Mouth Neoplasms, Oropharyngeal Neoplasms, Paranasal Sinus Neoplasms, Salivary Gland Neoplasms

NCT02875314 2026-02-12

HeadStart4: Newly Diagnosed Children (<10 y/o) With Medulloblastoma and Other CNS Embryonal Tumors

Phase 4 Active not recruiting

Medulloblastoma

NCT03734692 2026-02-12

Systemic Immune Checkpoint Blockade and Intraperitoneal Chemo-Immunotherapy in Recurrent Ovarian Cancer

Phase 1/2 Active not recruiting

24 enrolled 59 charts

Ovarian Cancer Recurrent

NCT04265872 2026-02-12

Bortezomib Followed by Pembrolizumab and Cisplatin in metTNBC

Phase EARLY_PHASE1 Recruiting

Breast Neoplasms

NCT05535166 2026-02-12

Molecular and Clinical Risk-Directed Therapy for Infants and Young Children With Newly Diagnosed Medulloblastoma

Phase 2 Recruiting

Brain Neoplasms, Medulloblastoma